Learn About Herpes Zoster Oticus

What is the definition of Herpes Zoster Oticus?
Herpes zoster oticus is a common complication of shingles, an infection caused by the varicella-zoster virus (which is the virus that also causes chickenpox). Shingles occurs in people who have had chickenpox and in whom the varicella-zoster virus becomes active again. Herpes zoster oticus is caused by the spread of the virus to facial nerves and can cause intense ear pain; a rash around the ear, mouth, face, neck, and scalp; and paralysis of the face. Other symptoms may include hearing loss, vertigo (feeling that the room is spinning), tinnitus (hearing abnormal sounds), nausea, vomiting, loss of taste in the tongue, and dry mouth and eyes.
Save information for later
Sign Up
What are the alternative names for Herpes Zoster Oticus?
  • Herpes zoster oticus
  • Facial nerve palsy due to VZV
  • Facial nerve palsy due to herpes zoster infection
  • Facial nerve paralysis due to VZV
  • Geniculate neuralgia
  • Hunt syndrome (formerly)
  • Hunt's syndrome (formerly)
  • Nervus intermedius neuralgia
  • Ramsay Hunt syndrome
  • Ramsay Hunt syndrome type 2 (formerly)
Who are the top Herpes Zoster Oticus Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Herpes Zoster Oticus Clinical Trials?
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 Variants

Summary: In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). The study will focus on participants with a specific genetic variant in their LRRK2 gene. The main question researchers are trying to answer is if taking BIIB122 slows the worsening of PD more than placebo in the early stages of PD. To help answer this question, r...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease

Summary: In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a ...

Who are the sources who wrote this article ?

Published Date: May 12, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Herpes Zoster Oticus?
Benefits of High-Dose Corticosteroid and Antiviral Agent Combination Therapy in the Treatment of House-Brackman Grade VI Ramsay Hunt Syndrome.
Intratympanic corticosteroid for Bell's palsy and Ramsay Hunt syndrome: Systematic review and meta-analysis.
Tired of the same old research?
Check Latest Advances
Acute Parkinsonism in a Patient with Spinal Cord Injury: A Case Report.